To test our hypothesis that HSP90/CDC37 antagonists are feasible anti-tumor agents in the treatment of HCC, we first tested their selective cytotoxicity against HCC cells (HepG2, Huh7, and Hep3B) compared to normal hepatocytes (Hu8114, Hu4175, and Hu8130, obtained from three donors with non-diseased liver). This evidence concerns the gene CDC37 and hepatocellular carcinoma.